APA (7th ed.) Citation

L, N., C, G., C, P., FJ, R., A, T., M, U., . . . TT, B. (2026). IGNITE: A phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma. Future oncology (London, England), 1. https://doi.org/10.1080/14796694.2026.2683574

Chicago Style (17th ed.) Citation

L, Nayak, et al. "IGNITE: A Phase III Study of Tirabrutinib Versus Rituximab and Temozolomide Combination Therapy in Relapsed/refractory Primary Central Nervous System Lymphoma." Future Oncology (London, England) 2026: 1. https://doi.org/10.1080/14796694.2026.2683574.

MLA (9th ed.) Citation

L, Nayak, et al. "IGNITE: A Phase III Study of Tirabrutinib Versus Rituximab and Temozolomide Combination Therapy in Relapsed/refractory Primary Central Nervous System Lymphoma." Future Oncology (London, England), 2026, p. 1, https://doi.org/10.1080/14796694.2026.2683574.